The Prostate Cancer Project


The Prostate Cancer Project is addressing the needs of improved detection and characterization of tumour extent, grade and biologic characterization of prostate cancer by developing a suite of emerging imaging techniques and combining these with existing “standard of care”.

The new generation imaging technologies being developed are (1) hyperpolarized 13C pyruvate/lactate imaging and (2) 23Na MRI imaging, both are using metabolic MRI to characterize prostate cancer, (3) prostate-specific membrane antigen (PSMA) targeted imaging and (4) software for maximizing data extraction from PET scans with 18F-fluorocholine imaging.

In parallel, the new pathology standard operating procedures and a common platform for 3D pathology to image fusion and tumour segmentation on digitized pathology are being developed to be used across sites to conduct a clinical protocol where pre-operative, multi-modality imaging will be obtained from men scheduled to undergo radical prostatectomy.

Finally, the mpMRI imaging is used in a pilot trial of focal therapy, which will serve as a “receptor” therapy for the validated new imaging techniques. Harmonized techniques for lesion identification and treatment using focal therapy is being established through the ITP Medical Instrumentation and Software Project.


  • DEVELOP: Translation of Hyperpolarized 13C Probes to Human Use, PI: Charles H. Cunningham, Sunnybrook Research Institute;
  • DEVELOP: Sodium MRI for Diagnosis of Prostate Cancer, PIs: Robert Bartha/Tim Scholl, University of Western Ontario;
  • DEVELOP: New Software for PET F-18 FCH Imaging, PI: Ting Lee, University of Western Ontario;
  • DEVELOP: New MI Probes for PC Detection, Staging and Guidance, PI:John Valliant, McMaster University;
  • VALIDATE: New Generation Imaging Against Digitized Histopathology Gold Standards, PI: Aaron Ward, London Health Sciences Centre Research Institute (Lawson);
  • APPLY: Multi-Institutional Implementation of Image Guided Focal Therapy, PIs: John Trachtenberg, UHN and Glenn Bauman, London Health Sciences Centre Research Institute (Lawson).

The Validate and Apply components are integrated into the OICR Improved Management of Early Cancer (IMEC) Translational Research Initiative.

Lead Principal Investigators

Dr. Glenn Bauman, London Health Sciences Centre Research Institute (Lawson)

Dr. Aaron Fenster, Robarts Research Institute, University of Western Ontario and Centre for Imaging Technology Commercialization